RecruitingPhase 3Phase 4ACTRN12605000551695
A comparison of artemisinin combination treatment in the form of Coartem® (artemether-lumefantrine) with sulfadoxine-pyrimethamine for treatment of uncomplicated malaria in Jhapa District, Nepal
Sponsor
RTI International
Enrollment
120 participants
Start Date
Aug 1, 2005
Study Type
Interventional
Conditions
Summary
To assess whether the existing treatment for uncomplicated malaria in eastern parts of the Terai in Nepal (supfadoxine-pyrimethamine) is still effective and to determine whether artemether-lumefantrine is a more effective alternative is a significant treatment failreu rate for SP is present
Eligibility
Sex: Both males and femalesMin Age: 5 Yearss
Inclusion Criteria1
- i) Uncomplicated falciparum or mixed falciparum/vivax infection, ii) Asexual parasite density >500/ul whole blood, iii) No prior antimalarial therapy within the last 3 months, iv) Temperature > 37.5C axillary, v) Absence of sensitivity to SP or chloroquine, vi) Ability to attend follow-up visits.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Artemether-lumefantrine or sulfadoxine pyrmethamine both given in recommended dose regimens (6 doses over 3 days for artemether-lumefantrine and a single dose for sulfadoxine pyrimethamine).
Artemether-lumefantrine or sulfadoxine pyrmethamine both given in recommended dose regimens (6 doses over 3 days for artemether-lumefantrine and a single dose for sulfadoxine pyrimethamine).
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000551695
Related Trials
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
NCT039378171 location
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
NCT066070031 location
Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
NCT026392991 location
FocaL Mass Drug Administration for Vivax Malaria Elimination
NCT056908411 location
Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
NCT011682712 locations